Best of ASCO - 2014 Annual Meeting

 

Welcome

Other/Nonsubtype Specific

Breast Cancer—Metastatic

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
[18F] Fluorodeoxyglucose positron emission (FDG-PET) in breast cancer: Clinical utility in neoadjuvant and metastatic setting.

Serafin Morales Murillo

e12584

A comparison of platinum-based chemotherapy versus capecitabine-based chemotherapy in the treatment of breast cancer metastasis to the liver.

Yimeng Chen

e12595

A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).

Ami N. Shah

1096

A phase II, single-arm study of apatinib and oral etoposide in pretreated metastatic HER2-negative breast cancer.

Nanlin Hu

1076

ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC).

Veronica Mariotti

1082

Association of secondary somatic mutations in BRCA1/2 with clinical resistance to PARP inhibitors and chemotherapy.

Lingjun Zhu

1087

Associations with response to poly (ADP-ribose) polymerase (PARP) inhibitors in metastatic breast cancer: Results of a meta-regression analysis.

Alexandra Desnoyers

e12567

Asymptomatic versus symptomatic metastatic breast cancer: Potential effects on prognosis and treatment strategies.

Sayaka Kuba

e12568

Chronobiological features of melatonin receptors (MT1) expression in breast cancer cells.

Alexandre Tavartkiladze

e12581

Clinical characteristics and outcome of metaplastic breast cancer: A retrospective tertiary care center experience.

Bicky Thapa

1095

Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients.

Özge Özer

e12572

Detection of subthreshold microsatellite instability in breast cancer: An ongoing investigation.

Joshua Z. Drago

1089

Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).

Mafalda Oliveira

1075

Development and validation of novel microenvironment-based immune molecular subtypes of breast cancer: Implications for immunotherapy.

Yunfang Yu

1094

Differences in breast cancer outcomes amongst Black United States-born and Caribbean-born immigrants.

Priscila Barreto Coelho

1088

Eribulin ORA: A novel oral formulation of eribulin based on combination with the P-gp inhibitor HM30181A.

Laura Pitzonka

e12577

Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC).

Reiki Nishimura

1083

Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients.

Damien Mikael Hansra

1098

First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 (RegistEM).

Carlos Jara

1077

First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.

Joyce O'Shaughnessy

1078

Fixed dose, dose-dense capecitabine in metastatic breast cancer.

Anne O'Dea

e12593

Gaps in metastatic breast cancer patient knowledge and understanding in Mexico.

Cynthia Villarreal-Garza

1090

Genome-wide chromosomal instability by cell-free DNA sequencing to predict patient survival in metastatic breast cancer.

Hongnan Mo

e12591

Genomic landscape of de novo stage IV breast cancer.

Ana Christina Garrido-Castro

1022

Histological growth pattern as a potential prognostic factor in patients operated for breast cancer liver metastases.

Ali Bohlok

e12576

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with metastatic breast cancer.

Xiaoxiang Guan

e12569

Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).

Tira Jing Ying Tan

1086

In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.

Yen-Shen Lu

1018

Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.

Charles McCrea

e12570

KX-ORAX-001: An open label, randomized, multicenter, phase III registrational study to determine the safety, tolerability, and tumor response of oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC).

Gerardo Antonio Umanzor Funez

TPS1116

Low-dose metronomic chemotherapy (LDMC) as an efficient treatment option in metastatic breast cancer: Results of an exploratory case-control study.

Marco Johannes Battista

e12578

Measuring on-treatment genome-wide tumor copy number alterations in cell-free DNA (cfDNA) in plasma is highly prognostic in metastatic breast cancer.

Adriana Aguilar

1097

Nab-paсlitaxel (Nab-P) in patients with metastatic breast cancer (mBC) with visceral crisis (VC): Efficacy and tolerability.

Kristina A. Novoselova

e12589

Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.

Romualdo Barroso-Sousa

TPS1115

NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).

Steven J. Chmura

TPS1117

Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.

Ming-Shen Dai

1084

Pathological and genetic aggressiveness of left-sided breast cancer.

Yara Abdou

e12579

Patients with metastatic breast cancer enrolled in phase I clinical trials: Clinical outcomes and cohort trends.

Jennifer Weiss

1099

Patterns of mutation enrichment in metastatic triple-negative breast cancer.

Cesar H. Saravia

e12596

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Ajjai Shivaram Alva

1014

Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.

Lawrence G. Lum

1080

Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC).

Ariel Ann Nelson

e12571

Prognostic significance of tartrate-resistant acid phosphatase expression in breast cancer.

Ming-Shen Dai

e12594

Prognostic value of circulating cytokines in breast cancer: A prospective study in sixty breast cancer patients in Tunisia.

Jihene Braham Ayari

e12592

Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.

Hongnan Mo

e12590

Real-world evidence evaluating the use of an NK-1 antiemetic in the systemic chemotherapy treatment of metastatic breast cancer.

Kevin Lord

e12599

Real-world evidence evaluating the use of single versus combination chemotherapy in salvage therapy for metastatic breast cancer.

Bruce A. Feinberg

e12600

Retrospective study of neuroendocrine breast cancer cases from a single institution in Québec.

Marie-Michèle Plante

e12588

Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC).

Adrienne Gropper Waks

1085

RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).

Anne Patsouris

1092

Sarcoidosis as a paraneoplastic syndrome for breast cancer.

Pamela Barletta

e12587

Satellite alpha transcript levels to predict risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer who lack BRCA-related clinical features.

Nao Kakizawa

e12575

Survival outcomes of premenopausal patients diagnosed with invasive lobular carcinoma.

Hee Jeong Kim

1093

TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients.

Cecile Vicier

1091

The landscape of palliative systemic therapy and overall survival of 2,063 advanced breast cancer patients in the China National Cancer Center.

Xiuwen Guan

e12583

The relationship of lncRNA NR2F1 and breast cancer angiogenesis via IL-8/lncRNA NR2F1/miR-200s/IL-8 loop.

Qi Zhang

e12573

Tracking the tumor evolution of patients with recurrence of ipsilateral breast tumor.

Yane Song

e12582

Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).

Paul W. Sperduto

1079

Use of a granulocyte colony-stimulating factor for the prevention of febrile neutropenia in the era of value-based care.

Bruce A. Feinberg

e12601